Furthermore, a study has provided compelling evidence that FFA2 agonists (Schiff periodic acid Schiff) can enhance insulin secretion through the activation of Gαq/PLC-mediated IP3 signaling and Ca2+ release.119 In recent years, the use of SCFAs in the treatment of T1DM has emerged as a potential novel therapeutic approach. This evidence concerns the gene INS and type 1 diabetes mellitus.